Document is current
Any future updates will be listed below
-
Authors
Feizpour, Azadeh https://orcid.org/0000-0003-0826-4011
Doré, Vincent https://orcid.org/0000-0002-8051-0558
Krishnadas, Natasha
Bourgeat, Pierrick
Doecke, James D. https://orcid.org/0000-0003-2863-0293
Saad, Ziad S.
Triana-Baltzer, Gallen
Laws, Simon M. https://orcid.org/0000-0002-4355-7082
Shishegar, Rosita
Huang, Kun
Fowler, Christopher
Ward, Larry
Masters, Colin L.
Fripp, Jurgen
Kolb, Hartmuth C. https://orcid.org/0000-0003-2414-5792
Villemagne, Victor L.
Rowe, Christopher C. https://orcid.org/0000-0003-3910-2453
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1132604, APP1140853, APP1152623)
Enigma Australia Pty Ltd
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 13 February 2025
First Online: 27 February 2025
Competing interests
: The authors declare the following competing interests: Christopher C. Rowe has received research grants from NHMRC, Enigma Australia, Biogen, Eisai and Abbvie. He is on the scientific advisory board for Cerveau Technologies and has consulted for Prothena, Eisai, Roche, and Biogen Australia. Victor L. Villemagne is and has been a consultant or paid speaker at sponsored conference sessions for Eli Lilly, Life Molecular Imaging, GE Healthcare, IXICO, Abbvie, Lundbeck, Shanghai Green Valley Pharmaceutical Co Ltd, AC Immune and Hoffmann La Roche. Ziad S. Saad, Gallen Triana-Baltzer, and Hartmuth C. Kolb are employees of Janssen Pharmaceuticals. Simon M. Laws is a scientific advisor for Cytox Ltd. The other authors did not report any conflict of interest.
